Structure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release

Current interferon-based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift toward combinations of direct-acting antivirals (DAA) with the first protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet primarily target only three viral proteins, na...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Toshana L, Thompson, Gary S, Kalverda, Arnout P, Kankanala, Jayakanth, Bentham, Matthew, Wetherill, Laura F, Thompson, Joseph, Barker, Amy M, Clarke, Dean, Noerenberg, Marko, Pearson, Arwen R, Rowlands, David J, Homans, Steven W, Harris, Mark, Foster, Richard, Griffin, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298801/
https://www.ncbi.nlm.nih.gov/pubmed/24022996
http://dx.doi.org/10.1002/hep.26685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298801/
https://www.ncbi.nlm.nih.gov/pubmed/24022996
http://dx.doi.org/10.1002/hep.26685

Ejemplares similares